FDA approves Genentech’s Tecentriq + Lurbinectedin in ES-SCLC

Genentech, a member of the Roche (RHHBY) Group, announced that the FDA has approved Tecentriq and Tecentriq Hybreza in combination with lurbinectedin for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with Tecentriq or Tecentriq Hybreza, carboplatin and etoposide. This approval marks the first and only combination therapy for the first-line maintenance treatment of ES-SCLC, a highly aggressive disease for which treatment options have been limited. The U.S. National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology have been updated to include the regimen as a category 2A and preferred option for maintenance treatment of people with ES-SCLC, following induction therapy with Tecentriq and CE.